SPRY — ARS PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ARS PHARMACEUTICALS INC (SPRY)
ARS PHARMACEUTICALS INC (SPRY) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $48M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in SPRY
How many top investors track SPRY
A small number of top investors own this.
SPRY Ownership Composition
How ARS PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other88.7%
- Hedge Funds11.3%
Tracked investors reporting SPRY
- Izzy EnglanderMar 31, 2026Millennium ManagementShares6MValue$48M% Portfolio0.02%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1.8MValue$14.8M% Portfolio0.00%
- Daniel LoebMar 31, 2026Third Point LLCShares1MValue$8M% Portfolio0.39%
Recent activity
- $36.9MFeb 17, 2026
- $48MMay 15, 2026
- New$14.8MMay 15, 2026
- New$6.5MFeb 17, 2026
- New$8MMay 15, 2026
- New$17.4MNov 14, 2025
Frequently asked questions
- How many institutional investors hold SPRY?
- 3 tracked institutional investors disclosed a position in SPRY (ARS PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of SPRY?
- Izzy Englander, Millennium Management, holds the largest disclosed position in SPRY, valued at $48M.
- Did institutional ownership of SPRY increase or decrease?
- Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 fully exited SPRY.
- Where does this SPRY ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.